ENTASIS THERAPEUTICS HOLDINGS INC. You should read the following discussion and analysis of our financial condition
and results of operations in conjunction with the unaudited consolidated
financial information and the notes thereto included in this Quarterly Report on
Form 10-Q and with our audited consolidated financial information and the notes
thereto included in our Annual Report on Form 10-K for the year ended
Overview
We are an advanced, late clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted antibacterial products
that address high unmet medical needs to treat serious infections caused by
multidrug-resistant pathogens. On
Our lead product candidate, sulbactam-durlobactam, or SUL-DUR, is an
intravenous, or IV, combination of sulbactam, an IV ?-lactam antibiotic, and
durlobactam, a novel broad-spectrum IV ?-lactamase inhibitor, or BLI, that we
are developing for the treatment of pneumonia and bloodstream infections caused
by carbapenem-resistant Acinetobacter baumannii, or Acinetobacter. Based on
current carbapenem resistance rates, we estimate there are in excess of 250,000
hospital-treated carbapenem-resistant Acinetobacter infections annually across
Our second late-stage product candidate, zoliflodacin, is a novel orally
administered molecule being developed for the treatment of uncomplicated
gonorrhea. The bacterial pathogen responsible for gonorrhea is Neisseria
gonorrhoeae, or N. gonorrhoeae, including multidrug-resistant strains.
Intramuscular injections of ceftriaxone now represent the only
23
Table of Contents
GARDP, which as the sponsor is also responsible for all Phase 3 clinical trial
and pharmaceutical development expenses. GARDP has commercial rights to
zoliflodacin in up to 168 low- and select middle-income countries, while Entasis
retains commercial rights in the major markets in
Our third product candidate is ETX0282CPDP which is a combination of a novel, oral BLI, ETX0282, with cefpodoxime proxetil or CPDP, which has the potential to address complicated urinary tract infections, or cUTIs, including those caused by multidrug-resistant Enterobacteriaceae. We believe there is a significant unmet need for new oral antibiotics to reliably treat the estimated 3 to 4 million patients diagnosed annually with cUTIs. We have reported preliminary Phase 1 trial results, and we are now seeking a partner to help further advance ETX0282CPDP through additional clinical trials. This program was previously supported by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program, or CARB-X.
We are also advancing the development of a novel class of antibiotics, non
?-lactam inhibitors of penicillin-binding proteins, or NBPs. We believe NBPs
constitute a potential new class of Gram-negative antibacterial agents that are
designed to target a broad spectrum of multidrug resistant bacterial pathogens
that overcome the main source of ?-lactam resistance which is driven by
?-lactamase activity. This novel class of agents is designed to potentially
target a broad spectrum of multidrug resistant bacterial pathogens that are part
of the
Since our inception in
Funding Arrangements
In
24
Table of Contents
CARB-X
In
License and Collaboration Agreements
GARDP
In
Zai Lab
In
Components of Results of Operations
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our preclinical and clinical product candidates. These expenses include:
employee-related expenses, including salaries and benefits, travel and
? stock-based compensation expense for employees engaged in research and
development functions;
? fees paid to consultants for services directly related to our product
development and regulatory efforts;
expenses incurred under agreements with contract research organizations, or
? CROs, as well as contract manufacturing organizations, or CMOs, and consultants
that provide supporting activities for our preclinical studies, clinical trials
and NDA filing and approval efforts;
? costs associated with preclinical activities and development activities;
? costs related to compliance with regulatory requirements; and
? facilities-related expenses, which include allocated rent and maintenance of
facilities and other operating costs.
25
Table of Contents
Costs associated with research and development activities are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.
Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and preclinical program and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under service, license or option agreements. We do not allocate employee costs or facility expenses to specific programs for financial reporting purposes because these costs are deployed across multiple programs and, accordingly, are not separately classified. We primarily use internal resources and our own employees to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities.
To date, substantially all of our research and development expenses have been
related to the preclinical and clinical development of our product candidates
and preclinical programs. The following table shows our research and development
expenses by development program and type of activity for the three months ended
Three Months Ended
March 31,
2022 2021
(in thousands)
Direct research and development expenses by program:
SUL-DUR $ 5,639 $ 4,030
ETX0462 95 1,192
ETX0282CPDP 4 60
Zoliflodacin - -
Other preclinical programs 637 216Unallocated research and development expenses: Personnel related (including stock-based compensation) 4,005 3,337 Facilities, supplies and other
612 535
Total research and development expenses $ 10,992 $ 9,370 Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.
The duration, costs and timing of clinical trials and development of our product candidates and preclinical program will depend on a variety of factors that include, but are not limited to, the following:
? the impact of COVID-19 on hospitals participating in the trials and their
ability to focus on and direct resources to our trials;
? the number of trials required for approval and any requirement for extension
trials;
26
Table of Contents
? per-patient trial costs;
? the number of patients that participate in the trials;
? the number of sites included in the trials;
? the countries in which the trials are conducted;
? the length of time required to enroll eligible patients;
? the number of doses that patients receive;
? the drop-out or discontinuation rates of patients;
? potential additional safety monitoring or other studies requested by regulatory
agencies;
? the duration of patient follow-up; and
? the efficacy and safety profiles of the product candidates.
Any changes in the outcome of any of these factors with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing and supply, and commercial viability. We will determine which programs to pursue and how much to fund each program based on the scientific and clinical success of each product candidate, as well as an assessment of each candidate's commercial potential.
General and Administrative Expenses
General and administrative expenses consist of salaries and benefits and stock-based compensation expense for personnel in executive, finance and administrative functions. General and administrative costs also include facilities-related costs not otherwise included in research and development expenses and professional fees for legal, patent, consulting, accounting, insurance and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research, development and commercialization activities of our product candidates. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing functions for that product candidate.
Other Income, Net Grant Income
Grant income consists of income recognized in connection with grants we received
under our funding arrangements with the Trustees of
Interest Income
Interest income consists of interest earned on our cash and investment balances,
which are primarily held in money market funds and
27
Table of Contents
Interest Expense
Interest expense consists of interest expense related to our convertible note.
Results of Operations
Comparison of the Three Months Ended
The following table summarizes our results of operations for the periods
presented:
Three Months Ended March 31,
2022 2021 $ Change
(in thousands)
Operating expenses:
Research and development $ 10,992 $ 9,370 $ 1,622
General and administrative 4,936 3,307 1,629
Total operating expenses 15,928 12,677 3,251
Loss from operations (15,928) (12,677) (3,251)
Other income, net:
Grant income 672 1,972 (1,300)
Interest income 4 4 -
Interest expense (10) - (10)
Total other income, net 666 1,976 (1,310)
Net loss $ (15,262) $ (10,701) $ (4,561) Research and Development Expenses
Research and development expenses were
General and Administrative Expenses
General and administrative expenses were
Other Income, Net
Other income, net was
28
Table of Contents
Liquidity and Capital Resources
Overview
As of
Going Concern
Since our inception, we have incurred recurring losses and negative cash flows
from operations. Our net loss was
These conditions and events raise substantial doubt about our ability to
continue as a going concern for one year following the issuance of
our consolidated financial statements for the quarter ended
Funding Requirements
Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, manufacturing development costs, legal and other regulatory expenses and general administrative costs.
The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the clinical development of our product candidates and obtain regulatory approvals. We are also unable to predict when, if ever, net cash inflows will commence from product sales. This is due to the numerous risks and uncertainties associated with developing drugs, including, among others, the uncertainty of:
? the unpredictable duration and economic impact of the COVID-19 pandemic;
? successful enrollment in, and completion of clinical trials;
performing preclinical studies and clinical trials in compliance with
? requirements of the FDA, the
comparable regulatory authority;
? the ability of collaborators to manufacture sufficient quantity of product for
development, clinical trials or potential commercialization;
29
Table of Contents
obtaining marketing approvals with labeling for sufficiently broad patient
? populations and indications, without unduly restrictive distribution
limitations or safety warnings, such as black box warnings or a risk evaluation
and mitigation strategies program;
? obtaining and maintaining patent, trademark and trade secret protection and
regulatory exclusivity for our product candidates;
? making arrangements with third parties for manufacturing capabilities;
? launching commercial sales of products, if and when approved, whether alone or
in collaboration with others;
? acceptance of the therapies, if and when approved, by physicians, patients and
third-party payors;
? competing effectively with other therapies;
? obtaining and maintaining healthcare coverage and adequate reimbursement;
? protecting our rights in our intellectual property portfolio; and
? maintaining a continued acceptable safety profile of our drugs following
approval.
A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.
We will not generate revenue from product sales unless and until we or a collaborator successfully complete clinical development and obtain regulatory approval for our current and future product candidates. If we obtain regulatory approval for any of our product candidates that we ultimately decide to commercialize on our own, we will incur significant expenses related to commercialization, including developing our internal commercialization capability to support product sales, marketing and distribution.
As a result, we will need substantial additional funding to support our continuing operations and to pursue our growth strategy. Until such time, if ever, when we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our failure to raise capital as and when needed would compromise our ability to pursue our business strategy.
We will also continue to incur costs as a public company that we did not incur
or incurred at lower rates prior to our initial public offering, including
increased fees payable to the nonemployee members of our board of directors,
increased personnel costs, increased director and officer insurance premiums,
audit and legal fees, investor relations fees and expenses for compliance with
public-company reporting requirements under the Exchange Act and rules
implemented by the
30
Table of Contents
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
Innoviva, Inc. Securities Purchase Agreements
On
On
The Convertible Note and the Warrants will have provisions that preclude conversion or exercise, respectively, if such conversion or exercise would result in the issuance of more than 19.99% of our currently outstanding common stock in the aggregate prior to obtaining stockholder approval.
Registration Rights Agreement
On
31
Table of Contents
Cash Flows
The following table summarizes our cash flows for the periods presented (in
thousands):
Three Months Ended
March 31,
2022 2021
Net cash used in operating activities $ (13,751) $ (10,099)
Net cash used in investing activities (9) (11)
Net cash provided by financing activities 15,000 1,800
Net increase (decrease) in cash and cash equivalents
Operating Activities
During the three months ended
During the three months ended
Investing Activities
During the three months ended
During the three months ended
Financing Activities
During the three months ended
During the three months ended
Critical Accounting Policies, Recent Accounting Pronouncements and Significant Judgments and Estimates
There have been no significant changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations," disclosed in our most recent Annual Report on Form 10-K.
Refer to Note 2, Summary of Significant Accounting Policies, in the accompanying notes to our unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.
32
Table of Contents
Our consolidated financial statements are prepared in accordance with generally
accepted accounting principles in
© Edgar Online, source
